Association of Serum Electrolytes, Serum 25-Hydroxycholecalciferol and Serum Thyroid Stimulating Hormone (TSH) in Irritable Bowel Syndrome (IBS)
Authors/Creators
- 1. Assistant Professor, Department of Biochemistry, NSMCH, Bihta, Patna.
- 2. Professor and Head, Department of Biochemistry, IGIMS, Patna.
- 3. Assistant Professor, Department of Biochemistry, ESIC Medical College and Hospital, Bihta, Patna.
- 4. Senior Resident, Department of Biochemistry, IGIMS, Patna.
- 5. Additional Professor, Department of General Medicine, IGIMS, Patna.
- 6. Scientist – I, Department of Biochemistry, IGIMS, Patna.
Description
Introduction: Irritable bowel syndrome (IBS) is one of the most prevalent, that affects up to 1 in 5 people over their lifetime. The Rome III committee defines IBS as a chronic functional disorder characterized by recurrent abdominal pain or discomfort associated with disordered defecation. Approximately 15 to 25% of the world population suffers from irritable bowel syndrome (IBS). Aim: To associate serum electrolytes, serum 25-hydroxy cholecalciferol and Thyroid Stimulating Hormones (TSH) in Irritable Bowel Syndrome (IBS). Objectives: To measure the serum electrolyte levels in patients with IBS and to compare the same with the serum electrolyte levels of normal healthy adults. Materials and Methods: A cross sectional study was conducted on 120 individuals 30-60 years age group, divided into 2 groups of 60 IBS cases and 60 apparently healthy control. Under aseptic precautions, 4 ml venous Blood was withdrawn from study participants, who visited to the department of general medicine and gastroenterology with symptoms of IBS on OPD basis and confirmed diagnosis of Irritable Bowel Syndrome (IBS) based on Rome’s criteria of IBS for cases and 60 samples collected from apparently healthy controls. S. potassium was estimated by fully automated analyser on DxC 700 AU. Serum TSH and serum 25-hydroxy cholecalciferol were estimated on abott architect i2000 SR that works on the principle of CMIA. Statistical analysis: All data was evaluated in the form of Mean ±SD and comparison was done based on pearson correlation coefficient. Then p value was calculated p<0.0001 was considered significant. Results: Serum chloride was considered to have significant p value when compared among cases and control. Serum TSH, serum sodium, serum potassium and serum 25-hydroxycholecalciferol gave non-significant results in cases of IBS when compared with controls. Discussion: IBS lacks acceptable bio-markers, and its diagnosis largely depends on the exclusion of underlying organic disease. Hence the diagnosis and management of this disorder can be challenging. maintaining normal serum electrolyte balance is essential for the efficient functioning of living cells. A follow up study would best suggest the efficient role of Vitamin D in IBS. Conclusion: The present study also tried to provide an insight into the possible changes that can be incorporated in the diet or serum electrolyte supplementation in IBS cases. Since the results were non-specific and statistically nonsignificant, further clinical studies are recommended with larger sample sizes for correlation of dyselectrolytemia.
Abstract (English)
Introduction: Irritable bowel syndrome (IBS) is one of the most prevalent, that affects up to 1 in 5 people over their lifetime. The Rome III committee defines IBS as a chronic functional disorder characterized by recurrent abdominal pain or discomfort associated with disordered defecation. Approximately 15 to 25% of the world population suffers from irritable bowel syndrome (IBS). Aim: To associate serum electrolytes, serum 25-hydroxy cholecalciferol and Thyroid Stimulating Hormones (TSH) in Irritable Bowel Syndrome (IBS). Objectives: To measure the serum electrolyte levels in patients with IBS and to compare the same with the serum electrolyte levels of normal healthy adults. Materials and Methods: A cross sectional study was conducted on 120 individuals 30-60 years age group, divided into 2 groups of 60 IBS cases and 60 apparently healthy control. Under aseptic precautions, 4 ml venous Blood was withdrawn from study participants, who visited to the department of general medicine and gastroenterology with symptoms of IBS on OPD basis and confirmed diagnosis of Irritable Bowel Syndrome (IBS) based on Rome’s criteria of IBS for cases and 60 samples collected from apparently healthy controls. S. potassium was estimated by fully automated analyser on DxC 700 AU. Serum TSH and serum 25-hydroxy cholecalciferol were estimated on abott architect i2000 SR that works on the principle of CMIA. Statistical analysis: All data was evaluated in the form of Mean ±SD and comparison was done based on pearson correlation coefficient. Then p value was calculated p<0.0001 was considered significant. Results: Serum chloride was considered to have significant p value when compared among cases and control. Serum TSH, serum sodium, serum potassium and serum 25-hydroxycholecalciferol gave non-significant results in cases of IBS when compared with controls. Discussion: IBS lacks acceptable bio-markers, and its diagnosis largely depends on the exclusion of underlying organic disease. Hence the diagnosis and management of this disorder can be challenging. maintaining normal serum electrolyte balance is essential for the efficient functioning of living cells. A follow up study would best suggest the efficient role of Vitamin D in IBS. Conclusion: The present study also tried to provide an insight into the possible changes that can be incorporated in the diet or serum electrolyte supplementation in IBS cases. Since the results were non-specific and statistically nonsignificant, further clinical studies are recommended with larger sample sizes for correlation of dyselectrolytemia.
Files
IJPCR,Vol15,Issue12,Article263.pdf
Files
(308.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:77427e0d79da6622cb5292ace56807a5
|
308.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-11-27
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue12,Article263.pdf
- Development Status
- Active
References
- 1. 1.Lacy BE, Rosemore J, Robertson D, et al. Physicians'attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol 2006; 41:892- 902. 2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006; 130:1480-1491 3. Thompson WG: A world view of IBS. In: Irritable Bowel Syndrome: Diagnosis and Treatment. 1st edition. Camilleri M and Spiller R (eds). Saunders, New York, NY, pp17-26, 2002. 4. Tinker MB. Discussion of paper by Verbrycke JR. Masked gastrointestinal hyperthyroidism. JAMA 1931; 97: 515-516. 5. Karaus M, Wienbeck M, Grussendorf M, Erckenbrecht JF, Strohmeyer G. Intestinal motor activity in experimental 6. hyperthyroidism in conscious dogs. Gastroenterology 1989; 97: 911-919. 7. Hoogendoorn EH, Cools BM. Hyperthyroidism as a cause of persistent vomiting. Neth J Med 2004; 62: 293-296. 8. Bassotti G, Pagliacci MC, Nicoletti I, Pelli MA, Morelli A. Intestinal pseudoobstruction secondary to hypothyroidism. Importance of small bowel manometry. J Clin Gastroenterol. 1992; 14: 56-58. 9. Ortiz LM, Saz-Peiró P, Sebastián-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig 2010;102:637-647. 10. Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108:1508- 1515. 11. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA 2015; 313:949-58. 12. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ (Clinical research ed) 2012;345:e5836. 13. Sprake EF, Grant VA, Corfe BM. Vitamin D3 as a novel treatment for irritable bowel syndrome: Single case leads to critical analysis of patient-centred data. BMJ Case Rep 2012;2012. 14. Khayyat Y, Attar S. Vitamin D deficiency in patients with irritable bowel syndrome: Does it exist? Oman Med J 2015;30:115-8. 15. Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013;108:1508- 1515. 16. Swathi Kamal, Shubha Jayaram, Sreenivas N, Dharmendra BL, Sudha B Sreenivas. Estimation of serum electrolytes in cases of irritable bowel syndrome and Healthy Adults: A comparative study. Indian Journal of Medical Biochemistry, Volume 23 Issue 1 (January-April 2019). 17. Vernia P, Latella G, Magliocca FM, et al. Seeking clues for a positive diagnosis of the irritable bowel syndrome. 1987;17(3):189-193.18. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003;111:931-943. 19. Michael C. Intestinal Secretory Mechanisms in Irritable Bowel Syndrome-Diarrhea. Clin Gastroenterol Hepatol 2015;13(6):1051-1057. 20. Hamm LR, Sorrells SC, Harding JP, Northcutt AR, Heath AT, Kapke GF, Hunt CM, Mangel AW. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol. 1999 May; 94(5):1279-82. 21. Hoogendoorn EH, Cools BM. Hyperthyroidism as a cause of persistent vomiting. Neth J Med 2004; 62: 293-296. 22. Karaus M, Wienbeck M, Grussendorf M, Erckenbrecht JF, Strohmeyer G. Intestinal motor activity in experimental hyperthyroidism in conscious dogs. Gastroenterology 1989; 97: 23. 911-919. 24. 22. Tenore A, Fasano A, Gasparini N, Sandomenico ML, Ferrara A, Di Carlo A, Guandalini S. Thyroxine effect on intestinal Cl-/HCO3- exchange in hypo- and hyperthyroid rats. J Endocrinol 1996; 151: 431-437. 25. 23. Thomas FB, Caldwell JH, Greenberger NJ. Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann Intern Med 1973; 78: 669-675. 26. Cashman MD, Martin DK, Dhillon S, Puli SR. Irritable bowel syndrome: A Clinical review. Curr Rheumatol Rev 2016;12:13-26. 27. 25. Bashir M, Prietl B, Tauschmann M, Mautner SI, Kump PK, Treiber G, et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr 2016;55:1479-89. 28. 26. Chirayath MV, Gajdzik L, Hulla W, Graf J, Cross HS, Peterlik M, et al. Vitamin D increases tight-junction conductance and paracellular ca2+transport in caco-2 cell cultures. Am J Physiol 1998;274:G389-96. 29. 27. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008;294:G208-16. 30. 28. Zhu T, Liu TJ, Shi YY, Zhao Q. Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. Int J Mol Med 2015; 35:1213-8. 31. Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in crohn's disease: Results from a randomised double-blind placebo-controlled study. United European Gastroenterol J 2015; 3:294-302 32. Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J Gastroenterol 2016; 22:933-48. 33. Jalili, M., Vahedi, H., Poustchi, H., & Hekmatdoost, A. Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, PlaceboControlled Clinical Trial. International journal of preventive medicine, 2019;10: 16.